Characteristics of patients with (Group 1) and without (Group 2) inflammation on MRI scan.
| Sex/Disease Subtype | Age at Diagnosis, yrs | Disease Duration at 1st Joint Symptoms, yrs | Disease Duration at MRI, yrs | Time to MRI*, days | Clinical Examination | RF/Anti-CCP | |||
|---|---|---|---|---|---|---|---|---|---|
| TJC/SJC | Tenosynovitis | FFC | |||||||
| Group 1 | |||||||||
| 2 | F/L | 22 | 12.0 | 12.3 | 14 | 2/6 | − | − | −/− |
| 4 | M/L | 68 | 0.0 | 1.9 | 31 | 20/10 | − | − | −/UK |
| 5 | F/D | 32 | −2.0 | 0 | 13 | 18/0 | − | + | 22/− |
| 6 | F/D | 36 | UK | 16.3 | 12 | 16/1 | − | − | 24/− |
| 7 | M/L | 60 | −0.8 | 1.5 | 70 | 0/ND | − | + | 40/− |
| 8 | F/L | 46 | UK | 13.7 | 8 | 0/0 | + | − | − |
| 11 | M/D | 44 | −1.2 | 0 | 21 | 0/10 | − | − | − |
| 13 | F/L | 59 | 1.9 | 2.3 | 44 | 1/1 | + | − | − |
| 16 | F/L | 50 | −1.6 | 2.3 | 49 | 4/0 | − | − | 48/18 |
| 17 | M/D | 37 | UK | 13.5 | 48 | 1/0 | − | + | − |
| Median (range) | 45 (22–68) | −0.8 (−2.8–12.0) | 2.3 (0–16.3) | 26 (8–70) | 2/1 | ||||
| Group 2 | |||||||||
| 1 | F/L | 52 | −1 | 0 | 13 | 22/7 | − | − | 32/− |
| 3 | M/D | 39 | UK | 0.5 | 41 | 2/0 | − | − | −/− |
| 9 | M/D | 45 | −0.2 | 2.6 | 53 | 8/3 | − | − | 25/UK |
| 10 | F/D | 54 | UK | 3.0 | 34 | 3/4 | − | − | −/− |
| 12 | MD | 37 | UK | 0.7 | 33 | 10/0 | − | + | −/UK |
| 14 | F/D | 48 | −0.5 | 7.3 | 55 | 7/4 | − | − | −/− |
| 15 | M/D | 46 | −0.4 | 0.2 | 33 | 19/4 | − | + | 249/90 |
| Median (range) | 46 (37–54) | −0.5 (−1.0 to −0.2) | 0.7 (0–7.3) | 34 (13–55) | 8/4 | ||||
↵* Time to MRI (from date of clinical examination). +: present, −: absent; L: limited, D: diffuse. TJC: tender joint count, SJC: swollen joint count, FFC: finger flexion contracture, ND: not determined (whole hand swollen), UK: unknown, RF: rheumatoid factor (negative < 20 IU/ml), anti-CCP: anti-citric citrullinated peptide antibody (negative ≤ 5 U/ml).